Anti-Vascular Endothelial Growth Factor Therapy as an Adjunct to Diabetic Vitrectomy

Introduction: The purpose of this work is to study the efficacy preoperative intravitreal administration bevacizumab as an adjunct vitrectomy in patients with Proliferative Diabetic Retinopathy (PDR). Methods: This retrospective comparative was performed on 118 eyes (118 patients) proliferative diabetic retinopathy (PDR), which underwent surgery at Department Eye Disease Zarifa Aliyeva National Ophthalmology Centre (Baku, Azerbaijan) 2015-2019. main group (the group) included 48 PDR that received (Avastin; Genentech Inc., USA) within one week before vitrectomy; control 70 did not receive a injection for least 3 months vitrectomy. minimum follow-up 12 months. Results: In both groups, complete retinal attachment after primary achieved all (100%). Clinically significant intraoperative haemorrhage observed 31.2% and group- 51.4%, p = 0.030. reduced risk clinically by 2.3 times need endodiathermy 2.7 (p 0.031 0.024, respectively). Early vitreous cavity 15.0% 35.5% 0.038). early postoperative period 3.0 0.036). Conclusion: use can help reduce incidence haemorrhage, leads better functional results period. Over long-term period, effect injections decreases.